
|Videos|March 29, 2021
Belantamab Mafodotin in Clinical Practice for Heavily Pretreated MM
Author(s)Targeted Oncology
Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
2
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Fast Track Designation to TER-2013 for Advanced Breast Cancer
5


































